Table 1.
Aggregate summarized clinical outcome results of 59 studies with 228 adult patients treated with biologics for allergic bronchopulmonary aspergillosis. Source: Reference [67].
| Biologic Agent | Studies Reviewed |
Patients Included |
Reduction in Total IgE | Reduction in Eosinophil Count | Reduction in Exacerbation Rate | Reduction in Steroid Use |
|---|---|---|---|---|---|---|
| Omalizumab | 36 | 133 | 45% | 70% | 90% | 66% |
| Mepolizumab | 13 | 62 | 67% | 95% | 85% | 98% |
| Benralizumab | 6 | 7 | 40% | 99% | 90% | 95% |
| Dupilumab | 4 | 26 | 65% | 48% * | 85% | 90% |
* following transient initial increase.